Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10111060 | 0.76 | KDM4E (0.49) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL21135009 | 0.76 | AKT1 (0.43) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL21135307 | 0.73 | AKT1 (0.42) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL21135039 | 0.73 | HTT (0.51) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL21135048 | 0.73 | ESR1 (0.55) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL21134993 | 0.71 | ESR1 (0.56) | AKT1HPGDAVPR1AKDM4EALDH1A1 | |
| SCHEMBL21135049 | 0.71 | TYMS (0.42) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL17023639 | 0.70 | AVPR1A (0.59) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL17069885 | 0.70 | AVPR1A (0.59) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E | |
| SCHEMBL17954875 | 0.70 | AKT1 (0.50) | AKT1HPGDSMN1; SMN2AVPR1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10818850-B2 | Organic electroluminescence device and compound including nitrogen for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-10-27 | — | — | US | disclosed |
| US-20190198773-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND COMPOUND INCLUDING NITROGEN FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190198773-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND COMPOUND INCLUDING NITROGEN FOR ORGANIC ELECTROLUMINESCENCE DEVICE | L1CAM, CHRM1, FOXM1 | AKT1 1494/4885HPGD 3402/4885SMN1; SMN2 1882/4885 |
| US-10818850-B2 | Organic electroluminescence device and compound including nitrogen for organic electroluminescence device | L1CAM, CHRM1, FOXM1 | AKT1 1494/4885HPGD 3402/4885SMN1; SMN2 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.